What does CJC-1295 without DAC do? Benefits and evidence
A peptide intended to trigger growth hormone release, with no human dosing study found.
Also called: Modified GRF 1-29, Mod GRF 1-29, Mod GRF(1-29), CJC-1295 no DAC.
GHRH analogues · Modified GHRH 1-29 analogue without an albumin-binding DAC tag.
“CJC-1295 no DAC” usually means modified GRF 1-29, a different molecule from trial-tested CJC-1295 with DAC. People often pair it with ipamorelin for sleep, recovery or body composition. No published human dosing study was found for this exact compound. Human half-life, effective dose and long-term safety remain unknown. It has no FDA approval.
- People report better sleep or recovery, while others report no benefit. (Reported by users)
- People report using it for muscle and body composition goals; no controlled human study has tested this. (Reported by users)
- People report pairing it with ipamorelin for exercise recovery; the benefit and safety of the pair are untested. (Reported by users)
Uses in the sources
- Users report body-composition and muscle goals. No controlled human benefit study for modified GRF 1-29 was found. (Reported by users) (source)
- Reported with ipamorelin for exercise recovery; benefit and combination safety are untested. (Reported by users) (source)
- Sleep reports conflict: some describe improvement, others disturbed sleep and vivid dreams. (Reported by users) (source)
Related to CJC-1295 without DAC
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- Sermorelin: An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
- CJC-1295 with DAC: An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- EGRIFTA WR (tesamorelin) for injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
- Supply unlicensed medicinal products (specials), MHRA · 2025
- December 4, 2024 Pharmacy Compounding Advisory Committee Meeting, FDA · 2024
- FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting December 4, 2024, US Food and Drug Administration · 2024
- Low blood sugar (hypoglycaemia), NHS · 2023
- Anticoagulant medicines - Side effects, NHS
- DailyMed - GLUCOTROL XL- glipizide tablet, extended release, Pfizer Inc. · DailyMed
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.